US FDA Will Allow Transitioning Products To Continue Referencing Drug Master Files

 
• By Derrick Gingery
FDABldg1ExteriorWithCircle_1200x675
The FDA's proposed rule is intended to ease the burden of the 2020 biologics transition process. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics